1
artículo
Publicado 2018
Enlace

El Carcinoma Hepatocelular es la segunda causa de muerte relacionada con cáncer en el mundo. Sorafenib, un inhibidor de tirosina quinasa, permanece en el estandar de la prescripción a pacientes con carcinoma hepatocelular avanzado o inoperable. Usando información de la red de investigación en hígado en Sud América (1336 casos de carcinoma hepatocelular) se creó un sistema de pronóstico costo-efectividad para ayudar a identificar a los pacientes con probabilidad del beneficio de sobrevivencia con el tratamiento con sorafenib.
2
artículo
Publicado 2023
Enlace

BACKGROUND & AIMS: Genetic ancestry or racial differences in health outcomes exist in diseases associated with systemic inflammation (e.g., Covid-19). This study aimed to investigate the association of genetic ancestry and race with acute-onchronic liver failure (ACLF), which is characterized by acute systemic inflammation, multi-organ failure and high risk of short-term death. METHODS: This prospective cohort study analyzed a comprehensive set of data including genetic ancestry and race, among several others, in 1274 patients with acutely decompensated cirrhosis (ADC) who were nonelectively admitted to 44 hospitals from 7 Latin American countries. RESULTS: 395 (31.0%) had ACLF of any grade at enrollment. Patients with ACLF had higher median percentage of Native American genetic ancestry and lower median percentage of European ancestry than patients without ACLF (22.6% vs 12.9% and 53.4%...